Growth Stocks Overview: Growth stocks are appealing due to their potential for above-average financial growth, but they also come with higher risks and volatility, making it challenging to identify those that will succeed.
ANI Pharmaceuticals as a Growth Pick: ANI Pharmaceuticals (ANIP) is highlighted as a strong growth stock, boasting a favorable Growth Score and a Zacks Rank of #2, with projected earnings growth of 40.2% this year, significantly outpacing the industry average.
Cash Flow Growth Importance: ANI's year-over-year cash flow growth stands at 22.1%, well above the industry average of -5%, indicating strong financial health and the ability to expand without relying on external funding.
Earnings Estimate Revisions: Positive trends in earnings estimate revisions for ANI suggest potential stock price increases, reinforcing its position as a recommended growth investment for investors.
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 109.75 USD with a low forecast of 100.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ANIP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIP is 109.75 USD with a low forecast of 100.00 USD and a high forecast of 121.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 85.390
Low
100.00
Averages
109.75
High
121.00
Current: 85.390
Low
100.00
Averages
109.75
High
121.00
Guggenheim
Buy
maintain
$115 -> $124
2026-01-16
Reason
Guggenheim
Price Target
$115 -> $124
AI Analysis
2026-01-16
maintain
Buy
Reason
Guggenheim raised the firm's price target on ANI Pharmaceuticals to $124 from $115 and keeps a Buy rating on the shares, primarily driven by an increase to the firm's Cortrophin sales estimates following ANI's preliminary Q4 results and 2026 outlook earlier this week.
Guggenheim
Vamil Divan
Buy
maintain
$114 -> $115
2025-11-10
Reason
Guggenheim
Vamil Divan
Price Target
$114 -> $115
2025-11-10
maintain
Buy
Reason
Guggenheim analyst Vamil Divan raised the firm's price target on ANI Pharmaceuticals to $115 from $114 and keeps a Buy rating on the shares. The firm is updating its model after the company reported "yet another beat and raise quarter" and following its follow-up conversation with management.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANIP
Unlock Now
JPMorgan
NULL -> Overweight
maintain
$95 -> $115
2025-09-24
Reason
JPMorgan
Price Target
$95 -> $115
2025-09-24
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on ANI Pharmaceuticals to $115 from $95 and keeps an Overweight rating on the shares. The firm remains bullish on the company's Cortrophin Gel, which it views as a \"highly-durable\" growth driver for ANI.
H.C. Wainwright
Brandon Folkes
maintain
$93 -> $121
2025-09-17
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$93 -> $121
2025-09-17
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on ANI Pharmaceuticals to $121 from $93 and keeps a Buy rating on the shares. The firm says Cortrophin Gel script data continues to track ahead of its forecasts. In addition, the the addressable market for Cortrophin is larger larger previously modeled, with 500,000 acute gout flares offering a \"very significant opportunity, along with multiple other indications,\" the analyst tells investors in a research note.
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
